Breast cancer

Systemic therapy for HER2-positive early breast cancer

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Educational Objective: Gain insight into the selection of neoadjuvant (preoperative) and adjuvant (postoperative) systemic therapies in patients with HER2-positive early breast cancer.
Specialty: Medical oncology, Clinical oncology, (Obstetrics & Gynaecology), (Surgical Oncology)
Target Audience: CME (basic, intermediate), Residents (senior)
Latest update: January 2024
Background:

New trials and approvals of anti-HER2 agents have enriched the treatment options for HER2-positive early breast cancer. Escalation and de-escalation strategies are part of the treatment landscape.

Regulatory approval status of targeted therapies for early stage HER2-positive breast cancer (status 5 January 2024)